TBTC trials (68 participants with MIC data) |
Pyrazinamide pharmacokinetic parameters |
Predicted Cmax μg·mL−1 | 29.2 (25.6–35.0) |
Predicted AUC0–24 h μg·h·mL−1 | 306 (261–357) |
Pharmacodynamic parameters |
Predicted AUC0–24 h/MIC | 8.35 (5.36–12.7) |
Predicted Cmax/MIC | 0.775 (0.549–1.18) |
PanACEA MAMS-TB trial (86 participants) |
Pyrazinamide pharmacokinetic parameters |
Predicted Cmax μg·mL−1 | 37.2 (33.4–40.9) |
Predicted AUC0–24 h μg·h·mL−1 | 331 (278–398) |
Rifampicin pharmacokinetic parameters |
Observed Cmax μg·mL−1 | |
Control: HR10ZE | 5.56 (5.08–7.26) |
Arm 1: HR35ZE | 26.7 (23.6–32.1) |
Arm 2: HR10ZQ | 3.65 (2.49–5.04) |
Arm 3: HR20ZQ | 12.1 (9.81–13.2) |
Arm 4: HR20ZM | 12.1 (9.83–14.4) |
Observed AUC0–24 h μg·h·mL−1 | |
Control: HR10ZE | 23.4 (17.4–29.3) |
Arm 1: HR35ZE | 164 (131–199) |
Arm 2: HR10ZQ | 18.3 (10.8–23.5) |
Arm 3: HR20ZQ | 66.3 (56.7–82.9) |
Arm 4: HR20ZM | 61.7 (50.5–78.7) |